Project Grant R03DK140290

This $659,358 federal project grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to investigate the biological mechanisms underlying kidney disease associated with APOL1 genetic variants in people of African ancestry. The primary objectives are to 1) explore the relationship between APOL1 gene dose and kidney disease phenotype, 2) examine the role of APOL1 protein...

This $223,176 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) will support research on the impact of APOL1 copy number variations (CNVs) on kidney disease susceptibility in African Americans. The principal investigator will develop a computational approach to characterize the risk variant architecture of APOL1 CNVs and identify risk variant combinations in patients with...

This $231,270 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports a research project titled "Advancing CKD Risk Prediction: Exome-Wide Studies and Rare Variant Analysis Across Big Biobanks." The project aims to perform large-scale rare variant analyses involving 1 million participants by leveraging data from major biobanks,...

This $829,985 Project Grant was awarded on July 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at the University of Virginia to develop new Drosophila, mouse, and human podocyte models to study the interaction between HIV and APOL1-G1, a genetic risk factor associated with increased risk of HIV-related chronic kidney disease...

This federal Project Grant award of $739,540 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports the development of a third-generation polygenic risk score for chronic kidney disease, which aims to improve personalized risk prediction by incorporating more powerful genomic data and advanced statistical methods. The research will be conducted by...

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded a $755,853 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Illinois to evaluate the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for treating chronic kidney disease (CKD) associated with sickle cell disease (SCD). The 5-year project, running from September 2025 to June 2030, aims to determine if the SGLT2i drug empagliflozin can...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $200,000.00 to New York University School of Medicine to conduct a case-cohort study investigating novel determinants of risk for living kidney donors. The key objectives are to: 1) use qualitative research to inform recruitment strategies and messaging to maximize participation of...

This $888,000 project grant from the National Heart, Lung and Blood Institute will fund research into the role of oxidative signaling through Na/K-ATPase in chronic kidney disease-induced anemia. The awardee, Marshall University Research Corporation, will investigate how accelerated red blood cell eryptosis, or premature cell death, contributes to anemia development and progression in chronic kidney disease. Two specific aims will be pursued: 1) defining the role of adipocytes and global...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $128,286 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Broad Institute, Inc. in Cambridge, MA. The objective of this 2-year, 6-month project is to investigate the cellular mechanisms of lipid-induced toxicity (lipotoxicity) in kidney tubular epithelial cells and its contribution to the development of chronic kidney disease (CKD). The project...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $135,582 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of Oklahoma Health Sciences Center to construct a single-cell atlas of mouse and human cells in autosomal dominant polycystic kidney disease (ADPKD). The project aims to understand how molecular and cellular pathways found in ADPKD patients correlate to mouse models, and to identify inter-...